CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases.
The price has broken the triangle, and we can expect a bullish trend from here.
Summary of analysis and signal :
Entry point: 86
stop-loss: 76
Take profit 1: 95
Take profit 2: 110